In this latter cohort, PREDICT demonstrated an improved ability to estimate breast cancer-specific and overall survival in HER2-positive patients, compared to other prognostication tools such as PREDICT and Adjuvant! This evidence concerns the gene ERBB2 and breast carcinoma.